Medexus Pharmaceuticals Inc. (MDP.TO) is set to report its fiscal Q4 results after the market close on July 2, 2026. Analysts expect a modest EPS of CA$0.01. However, the company hasn't provided an actual EPS figure, leaving investors eager for insights into its ongoing performance.
On July 2, 2026, Medexus will release its earnings for the fourth quarter of fiscal year 2026, which ended on June 30. While the market anticipates an EPS of CA$0.01, the lack of an actual figure raises questions about the company's financial health and future outlook. With a market cap of CA$161.47 million and a forward P/E ratio of 9.96x, investors are keen to see how the company navigates its challenges.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Long-term investors should watch Medexus' ability to generate positive earnings as it continues to develop its product pipeline.
Earnings Expectations vs. Reality: What Investors Should Note
With an EPS estimate of CA$0.01 and no actual figure reported, the uncertainty around Medexus' earnings performance may lead to increased scrutiny from investors. The company’s forward P/E of 9.96x suggests that the market is pricing in a cautious outlook, especially given its recent history of losses.
Advertisement
Bull case
- Product Performance: The recent announcement of strong fiscal year results shows positive momentum for GRAFAPEX (treosulfan) for Injection, which could boost future revenues.
- Market Position: Medexus has a relatively low forward P/E ratio compared to industry peers, indicating potential for growth if the company can improve profitability.
- Strategic Deals: The licensing agreement for UM171 Cell Therapy could enhance Medexus' product offerings and market reach.
Bear case
- Profitability Concerns: Medexus currently has a negative profit margin of -2.41%, highlighting ongoing challenges in achieving profitability.
- Lack of Recent News: The absence of significant updates or announcements in the last week might signal stagnation or lack of momentum in the business.
- Market Volatility: The stock's performance has fluctuated between CA$2.47 and CA$5.23 over the past year, reflecting uncertainty that could worry investors.
Medexus Pharmaceuticals Inc. (MDP.TO)
Overview: Medexus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients. What the screen shows: The company has a market cap of CA$161.47 million and a forward P/E ratio of 9.96x. Its recent performance has seen fluctuations, with a 52-week high of CA$5.23 and a low of CA$2.47. Risks and watch items: Investors should be cautious of the company's negative profit margin of -2.41% and the lack of recent news, which may indicate potential challenges ahead. For more information, visit Medexus Pharmaceuticals Inc.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
